VRTX Stock Recent News

Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Duncan McKechnie - COO Charles Wagner - EVP & CFO Conference Call Participants Geoffrey Meacham - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Merrill Lynch Evan Seigerman - BMO Capital Markets Michael Yee - Jefferies Liisa Bayko - Evercore ISI Eliana Merle - UBS David Risinger - Leerink Gena Wang - Barclays Operator Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 Earnings Call. [Operator Instructions].

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.06 per share, missing the Zacks Consensus Estimate of $4.22 per share. This compares to earnings of $4.76 per share a year ago.

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

In 2025, Wall Street has been rattled with increasing concerns about U.S.-China trade wars, escalating geopolitical pressures, rising economic uncertainties, and growing recession fears. The benchmark S&P 500 index is down nearly 4.7% in 2025.

Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the summer.

Nearly every investor has heard the adage, "Sell in May and go away." The premise is that stock market returns are often lower between May and October than from November to April.

Vertex Pharmaceuticals (VRTX) reachead $509.47 at the closing of the latest trading day, reflecting a +1.19% change compared to its last close.

Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!